BIO-GENE TECHNOLOGY LTD

Quarterly Activities Report and Appendix 4C

Bio-Gene Reports Strong Development, Efficacy and Partnering Progress during Q1 FY26

Q1 FY26 Highlights

- **Completed annual strategic review of product pipeline and strategic partnering priorities across the public health, consumer and crop protection sectors**
- **Additional product applications for both Flavocide® and Qcide® have been identified for assessment following interest from potential new commercial partners**
- **Several opportunities to develop and launch new products containing Qcide active ingredient, with shorter market entry timelines, have been identified**
- **Bio-Gene and its commercial partners continue to invest in the development and assessment of new Flavocide formulations best suited to its target applications**
- **Positive Flavocide efficacy results presented at a leading conference on tick-borne diseases by researchers from Purdue University**
- **14th harvest of Qcide completed with substantial progress assessing the biomass pre-treatment and extraction to optimise oil yield**
- **Commencement of two development programs funded by grants from the US Department of Defense under the Deployed Warfighter Protection (DWFP) Program**
- **Bio-Gene Management completed a series of meetings with current and potential commercial and research partners in Singapore, India and Japan**
- **Bio-Gene promoted its development products at two major conferences**
- **Completed second tranche of Placement – total gross proceeds from Placement and Share purchase Plan (SPP) of A$2.46m before costs**

Bio-Gene Technology Limited (**ASX:BGT**, "**Bio-Gene**" or "**the Company**"), an Australian agtech company developing the next generation of novel insecticides derived from nature, provides an update on activities for the quarter ended 30 September 2025 (Q1 FY26).

Bio-Gene is focused on advancing the development and regulatory approval of Flavocide and Qcide, Bio-Gene's two novel insecticidal active ingredients derived from nature. These compounds have novel modes of action and are being developed by Bio-Gene to address critical gaps in global pest control markets, including crop protection, public health and consumer applications, where resistance to conventional chemistries is rising and regulatory pressure is increasing.

Bio-Gene Technology Limited
ABN: 32 071 735 950
Level 6, 400 Collins Street, Melbourne, VIC 3000

Commenting on the focus during Q1 FY26, Managing Director & CEO Tim Grogan said:

"This quarter has seen very strong progress across a wide range of our strategic priority areas, including the development of further data required to support the registration of Flavocide, the new opportunities for Qcide and engagement with our current and potential commercial partners. It was also very pleasing to see the strong Flavocide efficacy data against ticks presented by Purdue University and the initiation of programs funded by the US Department of Defense. Bio-Gene's international profile is certainly growing rapidly as a result of our recent progress."

Annual Review of Pipeline and Strategic Priorities Completed

Bio-Gene has previously presented its pipeline of eight target products and use-patterns containing either Flavocide or Qcide, focused on commercially attractive market opportunities in the public health, consumer and crop protection sectors. This pipeline has been reviewed during the quarter based on technical and commercial progress to date and the Company's priorities. Each of these eight product opportunities remain as current priorities.

In addition, interest from new potential commercial partners and new data generated by the Company has opened up additional potential commercial and product applications for both Flavocide and Qcide that were not considered at the time of the Company's last strategic review.

Although the details of these additional potential applications remain confidential, Bio-Gene is engaged in activities to assess the merits of each. The growing interest in new insecticidal actives derived from nature and in new modes of action to combat increasing levels of resistance explains some of these new opportunities. In addition, the Company's growing familiarity with the beta-triketone class of compounds covering both Flavocide and Qcide has also contributed to consideration of broader applications of the Company's technology.

Similarly, Bio-Gene has now developed a pipeline of potential and confidential commercial partnering opportunities, in addition to the Company's previously announced commercial partners. This pipeline is diverse and these interactions are at various stages in their evolution, typically involving efficacy testing of formulated prototype products against target insects of interest.

Although Bio-Gene continues to be highly focused on the development of both Flavocide and Qcide as regulated new insecticidal actives, the Company is assessing additional potential applications of these two compounds internationally. For example, Qcide's additional opportunities relate to potential product applications that may have a faster route to market and an earlier product launch date than was previously anticipated, leading to earlier revenue generation opportunities for the Company.

Flavocide Development – Safety & Formulation

Following completion of the Placement and Share Purchase Plan and receipt of the proceeds of the Company's recent capital raise, Bio-Gene has been undertaking the preparatory stages of several major studies to assess the safety of Flavocide. The data to be generated from these studies will form a significant component of the dossier to be filed with the Australian Pesticides and Veterinary Medicines Authority (**APVMA**).

Bio-Gene intends to make separate announcements relating to these major studies in the near future, including a summary of their design and other relevant aspects and the updated pathway to regulatory submission of the Flavocide dossier in Australia.

In addition, during the quarter, Bio-Gene has continued to invest in new formulations of Flavocide relevant to the Company's target markets, while its commercial partners continue to invest in the development and assessment of formulations best suited to their needs. This work remains confidential to Bio-Gene and its commercial partners.

Bio-Gene Technology Limited
ABN: 32 071 735 950
Level 6, 400 Collins Street, Melbourne, VIC 3000

Positive Flavocide Efficacy Results Against Ticks Presented in Chicago

On 10 September 2025 researchers from Purdue University, Indiana, USA, presented promising new data on Flavocide at the *17th International Conference on Lyme Borreliosis and Other Tick-Borne Diseases* in Chicago, USA. This major international conference was attended by the most knowledgeable investigators in the field to share scientific discoveries relevant to serious infectious diseases transmitted by *Ixodes* ticks[1].

The presentation by researchers Maria Murgia, Phurchhoki Sherpa and Professor Catherine Hill from the Department of Entomology at Purdue University titled '*Assessment of New, Natural Product Formulation to Control Ticks in the Midwest, United States*' described laboratory studies showing that Flavocide formulated in a prototype emulsion in water formulation achieved greater than 90% mortality of *Ixodes scapularis* nymphs within 24 hours of exposure, validating its acaricidal potential. Residual activity was observed for up to four weeks under controlled laboratory conditions.

Under this program, the researchers plan to undertake additional field validation of Flavocide's effect on *Ixodes scapularis* nymphs and techniques to observe their behaviour in the presence of Flavocide.

Qcide Development – Harvest & Preparation for Scaled-up Production

In July 2025 the 14th Qcide harvest was completed, with further optimisation of the biomass pre-treatment to oil extraction and other yield improvements. The next harvest is scheduled for February 2026.

US Department of Defense Deployed Warfighter Protection (DWFP) Program

Both of the DWFP programs have been initiated. They are 'Flavocide passive emanator for control of flying insect vectors' (total grant US$972,449) and 'Qcide indoor insect barrier spray against bed bugs & flies' (total grant US$892,492). Device prototypes containing Flavocide have been developed for entomology testing.

Promotion of Bio-Gene Technology – Business Development & Conferences

As part of Bio-Gene's current partnerships and its strategy to engage with additional partners, management has recently completed a series of important meetings in Singapore, India and Japan.

In addition, management recently attended the Pesticon Pest Control Conference in Adelaide and the Mosquito Control Association of Australia & Arbovirus Research Symposium in Torquay, Victoria, to engage with industry professionals and promote Bio-Gene and its development products.

---

[1] *Ixodes* is a genus of hard-bodied ticks (family *Ixodidae*). It includes important disease vectors of animals and humans (tick-borne disease), and some species (notably *Ixodes holocyclus*) inject toxins that can cause paralysis. Some ticks in this genus may transmit the pathogenic bacterium *Borrelia burgdorferi* responsible for causing Lyme disease. Additional organisms that may be transmitted by *Ixodes* are parasites from the genus *Babesia*, which cause babesiosis, and bacteria from the related genus *Anaplasma*, which cause anaplasmosis.

Bio-Gene Technology Limited
ABN: 32 071 735 950
Level 6, 400 Collins Street, Melbourne, VIC 3000

Recent International Developments & Context for the Future Use of Flavocide & Qcide

During Q1 FY26 the following international developments have been reported:

- *Record outbreaks*: The European Centre for Disease Prevention and Control (**ECDC**) declared a "*new normal*" for mosquito-borne diseases, citing record-breaking outbreaks of West Nile virus and Chikungunya
- *Longer transmission seasons*: Rising temperatures, longer summers, and changes in rainfall have led to longer and more intense transmission seasons for mosquito-borne diseases across Europe
- *West Nile Virus*: In Europe infections have been reported in new areas of Europe, including provinces in Italy and Romania, and Europe recorded its highest number of West Nile virus cases in three years
- *Zika cases surge*: Zika cases have seen a significant rise in the Americas, with 720 reported for 2025 compared to 56 in 2024, and the presence of the virus increasing in Argentina. Costa Rica has also seen a consistent increase in reported cases over the past few years
- *Chikungunya in the Indian Ocean Region*: The World Health Organization (**WHO**) reported a significant resurgence of chikungunya in 2025, with large outbreaks on Indian Ocean islands and spread to countries like Madagascar, Somalia, Kenya, and India
- *Dengue outbreak in the Pacific Islands:* Emergency declarations have been made in several countries, including Kiribati, Nauru, Samoa and Tuvalu, that have experienced their largest dengue outbreak in a decade, with high numbers of cases and some fatalities.

Completion of Tranche 2 of the Placement

Bio-Gene completed Tranche 2 of a placement (**Placement**) of shares and SPP following approval by the Company's shareholders at an extraordinary general meeting held on 14 July 2025. The issue of fully paid ordinary shares in the Company (**Shares**) under the Placement and the SPP during this quarter raised gross proceeds of A$965,000 before costs. As previously announced on 5 May 2025, this completed the total capital raised during May to July 2025 of $2.46 million.

In addition to the Shares issued under the Placement and SPP, shareholders also approved the issue of:

- 55,035,096 unlisted 2028 Options exercisable at 3.4 cents per option, expiring on 15 May 2028; and
- 55,035,096 unlisted 2030 Options exercisable at 4.6 cents per option, expiring on 15 May 2030.

Governance Items

During the quarter and to date the Company's independent audit for its FY25 financial reports was completed, the Company's FY25 Annual Report was published and arrangements have been made for the Company's Annual General Meeting to be held on 19 November 2025.

In addition, as a result of the sequence of events in mid/late September 2025 leading up to release of the Company's announcement on 23 September 2025, the Company plans to: (1) strengthen protocols for managing third-party collaborative research, the release of results of this research, and conference presentations involving potentially market-sensitive information; (2) enhance internal escalation procedures for assessing disclosure obligations under Listing Rule 3.1 and the carve-outs under Listing Rule 3.1A; and (3) provide targeted internal training on ASX's expectations regarding confidentiality and disclosure timing, including the use of trading halts or voluntary suspensions where appropriate.

Bio-Gene Technology Limited
ABN: 32 071 735 950
Level 6, 400 Collins Street, Melbourne, VIC 3000

Outlook

Bio-Gene's engagement with current and potential commercial partners for new product applications containing Flavocide and Qcide indicates the growing global interest in the use of insect control products derived from nature. The Company is making strong progress generating the data required to support its application for registration of Flavocide and is focused on the opportunity to bring both Flavocide and Qcide to market as soon as possible.

Approved for release by the Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright, NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and toxicity. Its unique products are based on a naturally occurring class of compounds proven to overcome resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited in Australia.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Bio-Gene Technology Limited

ABN	Quarter ended ("current quarter")
32 071 735 950	**30 September 2025**

Consolidated statement of cash flows		Current quarter $A'000	Year to date $A'000
1.	**Cash flows from operating activities**		
1.1	Receipts from Tax Incentive	107	107
1.2	Payments for		
	(a) commercialisation expenses	(78)	(78)
	(b) research and development	(497)	(497)
	(c) intellectual property	(51)	(51)
	(d) professional services	(16)	(16)
	(e) directors' expenses	(47)	(47)
	(f) administration and corporate costs (see note 6)	(106)	(106)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	9	9
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(679)**	**(679)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:	-	-
	(a) entities		
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	965	965
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(25)	(25)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(51)	(51)
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (share proceeds received in advance)		
3.10	**Net cash from / (used in) financing activities**	**889**	**889**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,138	1,138
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(679)	(679)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	889	889
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**1,348**	**1,348**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	95	79
5.2	Call deposits	653	559
5.3	Bank overdrafts	-	-
5.4	Other (Term Deposits)	600	500
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,348**	**1,138**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate number of payments to related parties and their associates included in item 1	189
6.2	Aggregate number of payments to related parties and their associates included in item 2	N/A

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Note 6.1: Director's fees paid to Directors or their related entities plus remuneration paid to Executive Directors.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	N/A	N/A
7.2	Credit standby arrangements	N/A	N/A
7.3	Other (please specify)	N/A	N/A
7.4	**Total financing facilities**	**N/A**	**N/A**

7.5	**Unused financing facilities available at quarter end**	**N/A**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(679)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,348
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	**668**
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	0.98

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: Current level of negative operating cash flow is not expected to continue as the Company had lodged a R&D Tax Incentive claim expected to contribute towards operating cash flow in next quarter.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Yes, the Company is taking steps on raising funding through research grants, collaborators' contribution. Based on past experience, research grants are expected to continue.

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
Answer:	Yes, the Company is expected to continue its operations based on operational plan which is aligned with funding budget.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 October 2025

Authorised by: The Board of Directors

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – e.g. Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
6. Net movements in GST are included in this item.
7. Prior Quarter Corrections. Immaterial minor errors and reallocations of expenses from previous quarter reports are corrected on a year-to-date basis. Movements disclosed for the current quarter have been correctly calculated.